HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 61.1%

Neg 61.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.